


E. Vázquez, A. Galindo,* D. Gnecco,* S. Bernès, J. L. Terán and R. G. Enríquez

Tetrahedron: Asymmetry 12 (2001) 3209



(-)-(4*S*)-Ethyl-4-[3-(1'*S*-phenyl-ethylamino)-propyl]-cyclohex-2-enone hydrochloride


[α]_D = -50.5 (*c* = 1.0, CH₂Cl₂)

Source of chirality: (*S*)-(-)-1-phenylethylamine

Absolute configuration: 4*S*

E. Vázquez, A. Galindo,* D. Gnecco,* S. Bernès, J. L. Terán and R. G. Enríquez

Tetrahedron: Asymmetry 12 (2001) 3209



(+)-(4*R*)-Ethyl-4-[3-(1'*S*-phenyl-ethylamino)-propyl]-cyclohex-2-enone hydrochloride


[α]_D = +16 (*c* = 1.0, CH₂Cl₂)

Source of chirality: (*S*)-(-)-1-phenylethylamine

Absolute configuration: 4*R*

Xu-Chang He, Bin Wang, Gengli Yu and Donglu Bai*

Tetrahedron: Asymmetry 12 (2001) 3213



(*R*)-*N*-Ethyl-*N*-(4-hydroxybutyl)-1-[(*S*)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine



[α]_D = -326.2 (*c* 0.29, CHCl₃)

Source of chirality: resolution and stereoselective reactions

Absolute configuration: (*R*),1-(*S*)

Xu-Chang He, Bin Wang, Gengli Yu and Donglu Bai*

Tetrahedron: Asymmetry 12 (2001) 3213




(*R*)-*N*-Isopropyl-*N*-(4-hydroxybutyl)-1-[(*S*)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine

[α]_D = -325.4 (*c* 0.28, CHCl₃)

Source of chirality: resolution and stereoselective reactions

Absolute configuration: (*R*),1-(*S*)


 $C_{47}H_{47}FeNOP_2$

(R)-N-Benzyl-N-(4-hydroxybutyl)-1-[(S)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine

 $[\alpha]_D = -337.7$ (*c* 0.52, CHCl₃)

Source of chirality: resolution and stereoselective reactions

Absolute configuration: (R),1-(S)


 $C_{49}H_{51}FeNOP_2$

(R)-N-Benzyl-N-(4-hydroxy-4,4-dimethylbutyl)-1-[(S)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine

 $[\alpha]_D = -287.0$ (*c* 0.54, CHCl₃)

Source of chirality: resolution and stereoselective reactions

Absolute configuration: (R),1-(S)


 $C_{40}H_{41}FeNOP_2$

(R)-N-(4-Hydroxybutyl)-1-[(S)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine

 $[\alpha]_D = -263.3$ (*c* 0.51, CHCl₃)

Source of chirality: resolution and stereoselective reactions

Absolute configuration: (R),1-(S)


 $C_{43}H_{47}FeNOP_2$

(R)-N-Ethyl-N-(5-hydroxypentyl)-1-[(S)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine

 $[\alpha]_D = -265.3$ (*c* 0.12, CHCl₃)


Source of chirality: resolution and stereoselective reactions

Absolute configuration: (R),1-(S)

 $[\alpha]_D = -216.0$ (*c* 0.28, CHCl₃)


Source of chirality: resolution and stereoselective reactions

Absolute configuration: (R),1-(S)

(R)-*N*-Isopropyl-*N*-(5-hydroxypentyl)-1-[(S)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine $[\alpha]_D = -284.0$ (*c* 0.20, CHCl₃)


Source of chirality: resolution and stereoselective reactions

Absolute configuration: (R),1-(S)

(R)-*N*-Cyclopentyl-*N*-(5-hydroxypentyl)-1-[(S)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine $[\alpha]_D = -323.0$ (*c* 0.20, CHCl₃)

Source of chirality: resolution and stereoselective reactions

Absolute configuration: (R),1-(S)

(R)-*N*-Cyclohexyl-*N*-(5-hydroxypentyl)-1-[(S)-1',2-bis(diphenylphosphino)ferrocenyl]ethyl amine


5-Methyl-(3Z,5R,6Z)-3,6-dodecadienyl-5-hydroxypentaonate

E.e. = 90%

 $[\alpha]_D^{25} = +2.9$ (*c* 1.0, CHCl₃)

Source of chirality: enzyme-catalyzed transesterification

Absolute configuration: *R*




5-Ethyl-(3Z,5R,6Z)-3,6-dodecadienyl-5-hydroxypentaonate

E.e.=91%

 $[\alpha]_D^{25}=+11.0$ (*c* 1.2, CHCl₃)

Source of chirality: enzyme-catalyzed transesterification


Absolute configuration: *R*

5-Propyl-(3Z,5R,6Z)-3,6-dodecadienyl-5-hydroxypentaonate

E.e.=85%

 $[\alpha]_D^{25}=+5.2$ (*c* 1.0, CHCl₃)

Source of chirality: enzyme-catalyzed transesterification


Absolute configuration: *R*

5-Butyl-(3Z,5R,6Z)-3,6-dodecadienyl-5-hydroxypentaonate

E.e.=90%

 $[\alpha]_D^{25}=+9.8$ (*c* 1.0, CHCl₃)

Source of chirality: enzyme-catalyzed transesterification

Absolute configuration: *R*


5-Isobutyl-(3Z,5R,6Z)-3,6-dodecadienyl-5-hydroxypentaonate

E.e.=84%

 $[\alpha]_D^{25}=+6.2$ (*c* 1.1, CHCl₃)

Source of chirality: enzyme-catalyzed transesterification


Absolute configuration: *R*



E.e.=91%

 $[\alpha]_{\text{D}}^{25}=+1.9$ (*c* 1.0, CHCl₃)


Source of chirality: enzyme-catalyzed transesterification

Absolute configuration: *R*

E.e.=89%

 $[\alpha]_{\text{D}}^{25}=+10.1$ (*c* 1.0, CHCl₃)


Source of chirality: enzyme-catalyzed transesterification

Absolute configuration: *R*

E.e.=75%

 $[\alpha]_{\text{D}}^{25}=-19.2$ (*c* 1.0, CHCl₃)

Source of chirality: enzyme-catalyzed transesterification


Absolute configuration: *R*

E.e.=92%

 $[\alpha]_{\text{D}}^{25}=+12.4$ (*c* 1.0, CHCl₃)

Source of chirality: enzyme-catalyzed transesterification

Absolute configuration: *R*




5-Hydroxy-(3Z,5R,6Z)-3,6-dodecadienyl-5-hydroxypentaonate

E.e.=96%

 $[\alpha]_D^{25}=+13.0$ (*c* 1.0, CHCl₃)


Source of chirality: enzyme-catalyzed transesterification

Absolute configuration: *R*Bis [(*R*)-2-(7-benzyloxy-3-indolyl)-1-methylethylammonium] *O,O'*-di-*p*-toluoyl L-(2*R*,3*R*)-tartrate

D.e.=99.5%

 $[\alpha]_D^{20}=-71.8$ (*c* 1.00, MeOH)


Source of chirality: resolution

Absolute configuration: *R/R,R* $C_{18}H_{20}N_2O$
(*R*)-3-(2-Aminopropyl)-7-benzyloxyindole

E.e.=99.7%

 $[\alpha]_D^{20}=-17.8$ (*c* 0.50, MeOH)

Source of chirality: resolution


Absolute configuration: *R* $C_6H_9NO_3$
Methyl (*S*)-(-)-5-oxo-3-pyrrolidinecarboxylate

E.e.=76% (by chiral HRGC)

 $[\alpha]_D^{20}=-7.3$ (*c* 0.7, MeOH) $\Delta\epsilon_{209} -0.88$ (MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *S*



C₈H₁₃NO₃
Methyl (R)-(+)-1-ethyl-5-oxo-3-pyrrolidinecarboxylate


E.e.=95% (by chiral HRGC)

[α]_D²⁵=+8.7 (c 1.1, MeOH)

$\Delta\epsilon_{214}=+1.50$ (MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *R*



C₉H₁₅NO₃
Methyl (R)-(+)-1-(methyleneethyl)-5-oxo-3-pyrrolidinecarboxylate


E.e.=95% (by chiral HRGC)

[α]_D²⁵=+2.9 (c 0.7, MeOH)

$\Delta\epsilon_{213.4}=+1.83$ (MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *R*



C₁₀H₁₇NO₃
Methyl (S)-(-)-1-(1-butyl)-5-oxo-3-pyrrolidinecarboxylate


E.e.=96% (by chiral HRGC)

[α]_D²⁵=−5.0 (c 0.9, MeOH)

$\Delta\epsilon_{214}=-1.9$ (MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *S*



C₈H₁₃NO₄
Methyl (R)-(+)-1-(2-hydroxyethyl)-5-oxo-3-pyrrolidinecarboxylate


E.e.=99% (by chiral HRGC)

[α]_D²⁵=+8.4 (c 0.75, MeOH)

$\Delta\epsilon_{213}=+1.7$ (MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *R*



C₁₃H₁₅NO₃

Methyl (R)-(-)-1-(2-methylphenyl)-5-oxo-3-pyrrolidinecarboxylate


E.e.=99% (by chiral HRGC)

[α]_D²⁵=-19.0 (c 1.1, MeOH)

$\Delta\epsilon_{197}=-2.7$ (MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *R*



C₅H₇NO₃

(*R*)-(+)-5-oxo-3-Pyrrolidinecarboxylic acid


E.e.=34% (by chiral HRGC)

[α]_D²⁵=+10.2 (c 1.0, MeOH)

$\Delta\epsilon_{209}=+0.12$ (c 1.0, MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *R*



C₇H₁₁NO₃

(*S*)-(-)-1-Ethyl-5-oxo-3-pyrrolidinecarboxylic acid


E.e.=54% (by chiral HRGC)

[α]_D²⁵=-3.5 (c 1.0, MeOH)

$\Delta\epsilon_{214}=-1.20$ (MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: *S*



C₈H₁₃NO₃

(*S*)-(-)-1-(Methylethyl)-5-oxo-3-pyrrolidinecarboxylic acid


E.e.=88% (by chiral HRGC)

[α]_D²⁵=-2.4 (c 0.45, MeOH)


$\Delta\epsilon_{213.4}=-1.15$ (MeOH)

Source of chirality: enzymatic resolution


Absolute configuration: *S*




E.e. = 75% (by chiral HRGC)
 $[\alpha]_D^{25} = +3.7$ (*c* 1.0, MeOH)
 $\Delta e_{214} = +0.67$ (MeOH)
 Source of chirality: enzymatic resolution
 Absolute configuration: *R*



E.e. = 31% (by chiral HRGC)
 $[\alpha]_D^{25} = -4.4$ (*c* 1.0, MeOH)
 $\Delta e_{214} = -0.7$ (MeOH)
 Source of chirality: enzymatic resolution
 Absolute configuration: *S*





E.e. = 99% (by chiral HRGC)
 $[\alpha]_D^{25} = 15.5$ (*c* 0.5, abs. EtOH)
 $\Delta e_{197} = +1.66$ (MeOH)
 Source of chirality: enzymatic resolution
 Absolute configuration: *S*



E.e. >99%
 $[\alpha]_D^{20} +26.5$ (*c* 1.0, CHCl_3)
 $[\alpha]_D^{20} -24.0$ (*c* 1.0, MeOH)
 Source of chirality: enzymatic hydrolysis
 Absolute configuration: *R* (assigned by X-ray of derivative)

Arkadij Sobolev, Maurice C. R. Franssen,* Brigita Vigante, Brigit Cekavicus, Natalija Makarova, Gunars Duburs and Aede de Groot

Tetrahedron: Asymmetry 12 (2001) 3251



(-)3-[(Isobutyryloxy)methyl] 5-methyl (4R)-4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate

E.e. >99%


[α]_D²⁰ -17.6 (c 1.0, CHCl₃)

Source of chirality: chiral precursor

Absolute configuration: *R* (assigned by X-ray of derivative)

Arkadij Sobolev, Maurice C. R. Franssen,* Brigita Vigante, Brigit Cekavicus, Natalija Makarova, Gunars Duburs and Aede de Groot

Tetrahedron: Asymmetry 12 (2001) 3251



(-)3-Methyl 5-(2-propoxyethyl) (4R)-4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate

E.e. >99%


[α]_D²⁰ -19.7 (c 1.0, CHCl₃)

Source of chirality: chiral precursor

Absolute configuration: *R* (assigned by X-ray of derivative of precursor)

Arkadij Sobolev, Maurice C. R. Franssen,* Brigita Vigante, Brigit Cekavicus, Natalija Makarova, Gunars Duburs and Aede de Groot

Tetrahedron: Asymmetry 12 (2001) 3251



(-)4-[2-(Difluoromethoxy)phenyl]-5-(methoxycarbonyl)-2,6-dimethyl-1,4-dihydro-3-pyridinecarboxylic acid

E.e. >99%


[α]_D²⁰ -51.7 (c 1.0, CHCl₃)

Source of chirality: chiral precursor

Absolute configuration: *S* (assigned by X-ray of derivative)

A. J. Moreno-Vargas, J. G. Fernández-Bolaños, J. Fuentes and I. Robina*

Tetrahedron: Asymmetry 12 (2001) 3257




3-Ethoxycarbonyl-2-methyl-5-(1,2,3,4-tetra-O-benzyl-D-arabino-tetritol-1-yl)furan

[α]_D²⁵ = -31 (c 1.0, CH₂Cl₂)

Source of chirality: D-glucose

Absolute configuration: 1*S*,2*R*,3*R*; assigned by analogy with diastereomerically pure precursor and NMR




$[\alpha]_D^{25} = -26$ (*c* 2.8, CH₂Cl₂)

Source of chirality: D-glucose


Absolute configuration: 1*S*,2*R*,3*R*; assigned by analogy with diastereomerically pure precursor and NMR




3-Hydroxymethyl-2-methyl-5-(1,2,3,4-tetra-O-benzyl-D-arabino-tetritol-1-yl)furan



(*E*)-(6*S*,7*R*,8*R*)-6,7,8,9-Tetrabenzyloxy-3-hydroxymethylnon-3-ene-2,5-dione



2,3-Dihydroxymethyl-5-(1,2,3,4-tetra-O-benzyl-D-arabino-tetritol-1-yl)furan




5-(1,2,3,4-Tetra-O-benzyl-D-arabino-tetritol-1-yl)-3-(tert-butyldiphenylsilyloxymethyl)-2-methylfuran

$[\alpha]_D^{25} = -26$ (*c* 1.2, CH₂Cl₂)

Source of chirality: D-glucose

Absolute configuration: 1*S*,2*R*,3*R*; assigned by analogy with diastereomerically pure precursor and NMR




$C_{54}H_{56}O_7Si$
5-(1,2,3,4-Tetra-O-benzyl-D-arabino-tetritol-1-yl)-3-(*tert*-butyldiphenylsilyloxymethyl)-2-formylfuran

$[\alpha]_D^{25} = -26$ (*c* 2.5, CH₂Cl₂)

Source of chirality: D-glucose

Absolute configuration: 1*S*,2*R*,3*R*; assigned by analogy with diastereomerically pure precursor and NMR




$C_{54}H_{58}O_7Si$

(*E*)-(6*S*,7*R*,8*R*)-6,7,8,9-Tetrabenzyloxy-3-(*tert*-butyldiphenylsilyloxy)methylnon-3-ene-2,5-dione

$[\alpha]_D^{25} = -14$ (*c* 2.2, CH₂Cl₂)

Source of chirality: D-glucose

Absolute configuration: 6*S*,7*R*,8*R*; assigned by analogy with diastereomerically pure precursor and NMR




$C_{28}H_{30}O_7$
(4*R*,3*S*,1''*R*)-4-(3-Ethoxycarbonyl-2-methylfur-5-yl)-3-(1,2-diacetoxyethyl)-3,4-dihydro-1*H*-benzo[c]pyran

$[\alpha]_D^{25} = -84$ (*c* 1.4, CH₂Cl₂)

Source of chirality: D-glucose and C-arylation

Absolute configuration: 4*R*,3*S*,1''*R*; assigned by analogy with diastereomerically pure precursor and NMR




E.e. = 24.3%

$[\alpha]_D^{21} = +8.2$ (*c* = 6.5, CHCl₃)

Source of chirality: asymmetric synthesis catalyzed by (*R*)-HNL

Absolute configuration: (*R*)



(S)-2-Hydroxy-2-(5-bromo-2-thienyl)acetonitrile

E.e.=86%

[α]_D²¹=+19.7 (*c*=3.0, CHCl₃)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (S)




(S)-2-Hydroxy-2-(3-methyl-2-thienyl)acetonitrile

E.e.=65%

[α]_D²¹=+24.5 (*c*=5.0, CHCl₃)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (S)




(R)-2-Hydroxy-2-(2-(N-methyl)pyrrolyl)acetonitrile

E.e.=40.1%

[α]_D²¹=+35.7 (*c*=1.2, CHCl₃)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (R)




(R)-2-Hydroxy-2-(2-(N-methoxymethyl)pyrrolyl)acetonitrile

E.e.=81%

[α]_D²¹=+104.9 (*c*=0.7, CHCl₃)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (R)




(R)-2-Hydroxy-2-(2-(5-acetyl-N-methyl)pyrrolyl)acetonitrile

E.e. = 34.1%

 $[\alpha]_D^{21} = +38.8$ ($c = 0.8$, EtOH)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (R)




(R)-2-Hydroxy-2-(3-(5-cyano-N-methyl)pyrrolyl)acetonitrile

E.e. = 66.4%

 $[\alpha]_D^{21} = +24.7$ ($c = 0.8$, EtOH)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (R)

 $C_5H_4N_2OS$


(S)-2-Hydroxy-2-(2-thiazolyl)acetonitrile

E.e. = 67%

 $[\alpha]_D^{21} = +13$ ($c = 0.4$, EtOH)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (S)




(R)-2-Hydroxy-2-(6-bromo-2-pyridinyl)acetonitrile

E.e. = 65%

 $[\alpha]_D^{21} = +22.4$ ($c = 1.6$, CHCl₃)

Source of chirality: asymmetric synthesis catalyzed by (R)-HNL

Absolute configuration: (R)



C₁₀H₁₂O


(7aS)-Methyl-1,2,3,7a-tetrahydro-inden-5-one

E.e. = 70%

[α]_D -54 (*c* 1.42, CHCl₃)

Source of chirality: (*R*)-(+)1-phenylethylamine

Absolute configuration: 7aS



C₁₅H₂₀O₅


2-Acetoxy-propionic acid (3aS)-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1*H*-inden-(5*R*)-yl ester

E.e. ≥ 99%

[α]_D +46 (*c* 4.16, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 3aS,5*R*



C₁₅H₂₀O₅

2-Acetoxy-propionic acid (3a*R*)-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1*H*-inden-(5*S*)-yl ester


E.e. ≥ 99%

Mp 68–69°C (heptane–ether)

[α]_D -93 (*c* 1.98, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 3a*R*,5*S*



C₁₅H₂₀O₅


2-Acetoxy-propionic acid (3a*S*)-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1*H*-inden-(5*S*)-yl ester

E.e. ≥ 99%

[α]_D +39 (*c* 4.16, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 3a*S*,5*S*




2-Acetoxy-propionic acid (3aR)-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1*H*-inden-(5*R*)-yl ester

E.e. ≥99%

[α]_D -42 (*c* 2.11, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 3a*R*,5*R*




(6*R*)-Hydroxy-(7*aS*)-methyl-1,2,3,6,7,7a-hexahydro-inden-5-one

E.e. ≥99%

[α]_D +122 (*c* 2.15, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 6*R*,7*aS*




(6*S*)-Hydroxy-(7*aR*)-methyl-1,2,3,6,7,7a-hexahydro-inden-5-one

E.e. ≥99%

[α]_D -121 (*c* 1.98, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 6*S*,7*aR*



(6*S*)-Hydroxy-(7*aS*)-methyl-1,2,3,6,7,7a-hexahydro-inden-5-one


E.e. ≥99%

Mp 71–73°C (heptane–ether)

[α]_D +25 (*c* 1.35, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 6*S*,7*aS*



(6*R*)-Hydroxy-(7*a**R*)-methyl-1,2,3,6,7,7*a*-hexahydro-inden-5-one


E.e. ≥99%

Mp 71–73°C (heptane–ether)

[α]_D -24 (*c* 1.33, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 6*R*,7*a**R*



Acetic acid (3*a**S*)-methyl-6-oxo-2,3,3*a*,4,5,6-hexahydro-1*H*-inden-(5*R*)-yl ester


E.e. ≥99%

Mp 53–55°C (heptane–ether)

[α]_D +114 (*c* 2.28, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 3*a**S*,5*R*




Acetic acid (3*a**R*)-methyl-6-oxo-2,3,3*a*,4,5,6-hexahydro-1*H*-inden-(5*S*)-yl ester

E.e. ≥99%

[α]_D -112 (*c* 2.24, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 3*a**R*,5*S*




Acetic acid (3*a**S*)-methyl-6-oxo-2,3,3*a*,4,5,6-hexahydro-1*H*-inden-(5*S*)-yl ester

E.e. ≥99%

[α]_D +32 (*c* 1.55, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 3*a**S*,5*S*




Acetic acid (3a*R*)-methyl-6-oxo-2,3,3a,4,5,6-hexahydro-1*H*-inden-(5*R*)-yl ester

E.e. $\geq 99\%$

$[\alpha]_D -31$ (*c* 1.18, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 3a*R*,5*R*



(3a*S*)-Methyl-2,3,3a,4,5,6-hexahydro-1*H*-indene-(5*R*,6*R*)-diol


E.e. $\geq 99\%$

Mp 80–82°C (heptane–ether)

$[\alpha]_D +3$ (*c* 1.14, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 3a*S*,5*R*,6*R*



(3a*R*)-Methyl-2,3,3a,4,5,6-hexahydro-1*H*-indene-(5*S*,6*S*)-diol


E.e. $\geq 99\%$

Mp 80–82°C (heptane–ether)

$[\alpha]_D -3$ (*c* 1.08, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 3a*R*,5*S*,6*S*




(3a*S*)-Methyl-2,3,3a,4,5,6-hexahydro-1*H*-indene-(5*R*,6*S*)-diol

E.e. $\geq 99\%$

$[\alpha]_D +159$ (*c* 0.60, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 3a*S*,5*R*,6*S*



C₁₀H₁₆O₂


(3aR)-Methyl-2,3,3a,4,5,6-hexahydro-1*H*-indene-(5*S*,6*R*)-diol

E.e. ≥99%

[α]_D -152 (*c* 0.85, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 3a*R*,5*S*,6*R*



C₁₄H₂₀O₆

Acetic acid (9*S*)-acetoxy-(7*S*)-methyl-2,10-dioxa-tricyclo[5.3.1.0]undec-(3*R*)-yl ester


E.e. ≥99%

Mp 77–79°C (heptane–ether)

[α]_D -83 (*c* 1.08, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 1*R*,3*R*,7*S*,8*S*,9*S*



C₁₄H₂₀O₆

Acetic acid (9*R*)-acetoxy-(7*R*)-methyl-2,10-dioxa-tricyclo[5.3.1.0]undec-(3*S*)-yl ester


E.e. ≥99%

Mp 77–79°C (heptane–ether)

[α]_D +82 (*c* 1.08, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 1*S*,3*S*,7*R*,8*R*,9*R*



C₁₃H₂₄O₃


2-(2,2,5-trimethyl-hexahydro-benzo[1,3]dioxin-(5*S*)-yl)-ethanol

E.e. ≥99%

[α]_D +21 (*c* 1.74, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl lactyl chloride

Absolute configuration: 4a*S*,5*S*,8a*S*




2-(2,2,5-Trimethyl-hexahydro-benzo[1,3]dioxin-(5*S*)-yl)-ethanol

E.e. ≥99%

[α]_D +17 (*c* 1.08, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 4a*S*,5*S*,8a*R*




5-(2-Benzylxy-ethyl)-2,2,5-trimethyl-hexahydro-benzo[1,3]dioxine

E.e. ≥99%

[α]_D +8 (*c* 2.27, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 4a*S*,5*S*,8a*R*




5-(2-Benzylxy-ethyl)-2,2,5-trimethyl-hexahydro-benzo[1,3]dioxine

E.e. ≥99%

[α]_D +13 (*c* 2.35, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 4a*S*,5*S*,8a*S*




3-(2-Benzylxy-ethyl)-(2*R*)-(tert-butyl-dimethyl-silanyloxymethyl)-(3*S*)-methyl-cyclohexanone

E.e. ≥99%

[α]_D -22 (*c* 2.43, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 2*R*,3*S*



C₂₄H₄₀O₂Si


[2-(2-Benzylxyloxyethyl)-(2S)-methyl-6-methylene-(1S)-cyclohexilmethoxy]-*tert*-butyl-dimethyl-silane

E.e. ≥99%

[α]_D -18 (*c* 2.25, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 1*S*,2*S*



C₁₇H₃₄O₂Si


(2*S*)-[2-(*tert*-Butyl-dimethyl-silanyloxymethyl)-(1*S*)-methyl-3-methylene-cyclohexyl]-ethanol

E.e. ≥99%

[α]_D -36 (*c* 1.36, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 1*S*,2*S*



C₃₁H₆₄O₃SiSn


tert-Butyl-{(2*S*)-[(2*S*)-methoxymethoxy-(2*S*)-(tributylstannanyl)-ethyl]-(2*S*)-methyl-6-methylene-(1*S*)-cyclohexilmethoxy}-dimethyl-silane

E.e. ≥99%

[α]_D +19 (*c* 1.82, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 1*S*,2*S*,2*R*



C₃₁H₆₄O₃SiSn


tert-Butyl-{(2*S*)-[(2*R*)-methoxymethoxy-(2*R*)-(tributylstannanyl)-ethyl]-(2*S*)-methyl-6-methylene-(1*S*)-cyclohexilmethoxy}-dimethyl-silane

E.e. ≥99%

[α]_D -64 (*c* 2.30, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 1*S*,2*S*,2*R*



C₁₇H₃₂O₂Si


[(2S)-(tert-Butyl-dimethyl-silyloxy)methyl)-(1S)-methyl-3-methylene-cyclohexyl]-acetaldehyde

E.e. ≥99%

[α]_D -16 (*c* 1.36, CHCl₃)

Source of chirality: resolution with (*S*)-*O*-acetyl-lactyl chloride

Absolute configuration: 1*S*,2*S*




C₁₈H₂₇NO₂

(1'R)-1-(2'-Methoxy-1'-phenylethyl)azacyclodecan-2-one

[α]_D = -55.5 (*c* = 1.25, MeOH)

Source of chirality: (*R*)-(-)-1-amino-1-phenyl-2-methoxyethane

Absolute configuration: 1'R




C₁₉H₂₉NO₂

(1'R,3R)-1-(2'-Methoxy-1'-phenylethyl)-3-methylaza-cyclodecan-2-one

[α]_D = -45.4 (*c* = 0.625, MeOH)

Source of chirality: (*R*)-(-)-1-amino-1-phenyl-2-methoxyethane

Absolute configuration: 1'R,3R




C₁₉H₃₁NO

(1'R,3R)-1-(2'-Methoxy-1'-phenylethyl)-3-methylazacyclodecane

[α]_D = +43.8 (*c* = 0.99, MeOH)

Source of chirality: (*R*)-(-)-1-amino-1-phenyl-2-methoxyethane

Absolute configuration: 1'R,3R




C₁₀H₂₁N
(3*R*)-3-Methylazacyclodecane

[α]_D = +17.4 (*c* = 0.205, MeOH)

Source of chirality: (*R*)-(−)-1-amino-1-phenyl-2-methoxyethane

Absolute configuration: 3*R*




C₁₃H₂₈N₂
(3*R*)-1-(3'-Aminopropyl)-3-methylazacyclodecane

[α]_D = +74.6 (*c* = 0.925, MeOH)

Source of chirality: (*R*)-(−)-1-amino-1-phenyl-2-methoxyethane

Absolute configuration: 3*R*




C₁₀H₁₃NO₂
(*R*)-(−)-2-(3'-Methoxyphenyl)propionamide

E.e. >99%

[α]_D¹⁸ = −46.4 (*c* 1.7, CHCl₃)

Source of chirality: *Rhodococcus* sp. CGMCC 0497-catalyzed enantioselective hydrolysis of the corresponding nitrile

Absolute configuration: *R*




C₉H₁₀ClNO
(*R*)-(−)-2-(3'-Chlorophenyl)propionamide

E.e. >99%

[α]_D¹⁸ = −48.3 (*c* 1.25, CHCl₃)


Source of chirality: *Rhodococcus* sp. CGMCC 0497-catalyzed enantioselective hydrolysis of the corresponding nitrile

Absolute configuration: *R*

 $C_9H_{10}FNO$


(R)-(-)-2-(4'-Fluorophenyl)propionamide

E.e. >99%

 $[\alpha]_D^{18} = -44.5$ (*c* 1.2, CHCl₃)Source of chirality: *Rhodococcus* sp. CGMCC 0497-catalyzed enantioselective hydrolysis of the corresponding nitrileAbsolute configuration: *R* $C_9H_{10}BrNO$


(R)-(-)-2-(4'-Bromophenyl)propionamide

E.e. >98%

 $[\alpha]_D^{18} = -53.6$ (*c* 2.0, CHCl₃)Source of chirality: *Rhodococcus* sp. CGMCC 0497-catalyzed enantioselective hydrolysis of the corresponding nitrileAbsolute configuration: *R* $C_9H_{10}INO$


(R)-(-)-2-(4'-Iodophenyl)propionamide

E.e. >99%

 $[\alpha]_D^{18} = -39.8$ (*c* 0.25, CHCl₃)Source of chirality: *Rhodococcus* sp. CGMCC 0497-catalyzed enantioselective hydrolysis of the corresponding nitrileAbsolute configuration: *R*E.e. 94% de [by ¹H NMR] $[\alpha]_D^{20} = -79.6$ (*c* 0.3, CHCl₃)Source of chirality: (−)-(1*R*,2*S*,5*R*)-methyl chloroformate (ee 99%)Absolute configuration: a*R*(a*R*,1*R*,1*'R*,2*S*,2*'S*,5*R*,5*'R*)-[2,2',6,6'-Tetramethoxy-1,1'-biphenyl]-3,3'-diyl-*S,S'*-bis[5-methyl-2-(1-methylethyl)-cyclohexyl]-carbonic ester

Giovanna Delogu,* Davide Fabbri, Maria Antonietta Dettori,
Giuseppe Capozzi, Stefano Menichetti* and Cristina Nativi

Tetrahedron: Asymmetry 12 (2001) 3313



(*R*)-(-)-2,2',6,6'-Tetramethoxy-3,3'-dimercapto-1,1'-biphenyl

E.e. 94% ee [by ^1H NMR of the corresponding diastereomer]


$[\alpha]_D^{20} = -28.9$ (*c* 0.4, CHCl_3)

Source of chirality: resolution

Absolute configuration: *R*

Giovanna Delogu,* Davide Fabbri, Maria Antonietta Dettori,
Giuseppe Capozzi, Stefano Menichetti* and Cristina Nativi

Tetrahedron: Asymmetry 12 (2001) 3313



(*S*)-(+)-2,2',6,6'-Tetramethoxy-3,3'-dimercapto-1,1'-biphenyl

E.e. 76% ee [by ^1H NMR of the corresponding diastereomer, by chiral HPLC of the corresponding dithiomethyl derivative]


$[\alpha]_D^{20} = +23.6$ (*c* 1, CHCl_3)

Source of chirality: resolution

Absolute configuration: *S*

Francesca Paradisi,* Gianni Porzi and Sergio Sandri*

Tetrahedron: Asymmetry 12 (2001) 3319



$\text{C}_{13}\text{H}_{19}\text{NO}_2$

(*S*)-*N*-Benzylvaline methyl ester


$[\alpha]_D = -53.9$ (*c* 1.03, CHCl_3)

Source of chirality: L-valine

Absolute configuration: *S*

Francesca Paradisi,* Gianni Porzi and Sergio Sandri*

Tetrahedron: Asymmetry 12 (2001) 3319




$\text{C}_{15}\text{H}_{20}\text{NO}_3\text{Cl}$

(*S*)-*N*-Benzyl-*N*-chloroacetylvaline methyl ester



$[\alpha]_D = -78.8$ (*c* 1.06, CHCl_3)

Source of chirality: L-valine


Absolute configuration: *S*

(2*S*)-1-Benzyl-2-isopropylpiperazine-3,6-dione
 $[\alpha]_D +10.8 (c\ 1.012, \text{CHCl}_3)$


Source of chirality: L-valine

Absolute configuration: 2*S*(6*S*)-1-Benzyl-5-ethoxy-3,6-dihydro-6-isopropylpyrazine-2-one
 $[\alpha]_D +68 (c\ 1.01, \text{CHCl}_3)$

Source of chirality: L-valine


Absolute configuration: 6*S*1-[(3'*R*,6'*S*)-1'-Benzyl-5'-ethoxy-3',6'-dihydro-6'-isopropylpyrazin-3'-yl-2'-one]-3-[(3''*R*,6''*S*)-1''-benzyl-5''-ethoxy-3'',6''-dihydro-6''-isopropylpyrazin-3''-yl-2''-one]propane
 $[\alpha]_D +41.6 (c\ 1, \text{CHCl}_3)$

Source of chirality: L-valine

Absolute configuration: 3'*R*,6'*S*,3'',6''*S* assigned by ^1H NMR1-[(3'*R*,6'*S*)-1'-Benzyl-5'-ethoxy-3',6'-dihydro-6'-isopropylpyrazin-3'-yl-2'-one]-3-[(3''*S*,6''*S*)-1''-benzyl-5''-ethoxy-3'',6''-dihydro-6''-isopropylpyrazin-3''-yl-2''-one]propane
 $[\alpha]_D -20 (c\ 1.014, \text{CHCl}_3)$

Source of chirality: L-valine


Absolute configuration: 3'*R*,6'*S*,3'',6''*S* assigned by ^1H NMR

 $C_{21}H_{36}N_4O_4$

1-[(3'R,6'S)-5'-Ethoxy-3',6'-dihydro-6'-isopropyl-1'H-pyrazin-3'-yl-2'-one]-3-[(3''R,6''S)-5''-ethoxy-3'',6''-dihydro-6''-isopropyl-1''H-pyrazin-3''-yl-2''-one]propane

 $[\alpha]_D +108 (c\ 1,\ CHCl_3)$


Source of chirality: L-valine

Absolute configuration: 3'R,6'S,3''S,6''S assigned by 1H NMR $C_{38}H_{52}N_4O_4$

1-[(3'R,6'S)-3'-Allyl-1'-benzyl-5'-ethoxy-6'-hydro-6'-isopropylpyrazin-3'-yl-2'-one]-3-[(3''R,6''S)-1''-benzyl-5''-ethoxy-3'',6''-dihydro-6''-isopropylpyrazin-3''-yl-2''-one]propane

 $[\alpha]_D -10.7 (c\ 1,\ CHCl_3)$


Source of chirality: L-valine

Absolute configuration: 3'R,6'S,3''R,6''S assigned by 1H NMR $C_{44}H_{56}N_4O_4$

1-[(3'R,6'S)-1'-Benzyl-3'-benzyloxyacetyl-5'-ethoxy-6'-hydro-6'-isopropylpyrazin-3'-yl-2'-one]-3-[(3''R,6''S)-1''-benzyl-5''-ethoxy-3'',6''-dihydro-6''-isopropylpyrazin-3''-yl-2''-one]propane

 $[\alpha]_D -3.1 (c\ 1.014,\ CHCl_3)$

Source of chirality: L-valine


Absolute configuration: 3'R,6'S,3''R,6''S assigned by 1H NMR $C_{36}H_{49}ClN_4O_4$

1-[(3'R,6'S)-1'-Benzyl-3'-chloromethyl-5'-ethoxy-6'-isopropylpyrazin-3'-yl-2'-one]-3-[(3''R,6''S)-1''-benzyl-5''-ethoxy-3'',6''-dihydro-6''-isopropylpyrazin-3''-yl-2''-one]propane

 $[\alpha]_D -5.3 (c\ 1,\ CHCl_3)$

Source of chirality: L-valine

Absolute configuration: 3'R,6'S,3''R,6''S assigned by 1H NMR




$[\alpha]_D +94.3$ (*c* 1, CHCl₃)

Source of chirality: L-valine

Absolute configuration: 3'R,6'S,3''R,6''S assigned by ¹H NMR



1-[(3'R,6'S)-3'-Allyl-5'-ethoxy-6'-hydro-6'-isopropyl-1'H-pyrazin-3'-yl-2'-one]-3-[(3''R,6''S)-5''-ethoxy-3'',6''-dihydro-6''-isopropyl-1''H-pyrazin-3''-yl-2''-one]propane




$[\alpha]_D +58.3$ (*c* 1.01, CHCl₃)

Source of chirality: L-valine

Absolute configuration: 3'S,6'S,3''R,6''S assigned by ¹H NMR



1-[(3'S,6'S)-5'-Ethoxy-6'-hydro-6'-isopropyl-3'-methyl-1'H-pyrazin-3'-yl-2'-one]-3-[(3''R,6''S)-5''-ethoxy-3'',6''-dihydro-6''-isopropyl-1''H-pyrazin-3''-yl-2''-one]propane




$[\alpha]_D +9.1$ (*c* 0.316, CHCl₃)

Source of chirality: L-valine

Absolute configuration: 3'R,6'S,3''R,6''S assigned by ¹H NMR



1-[(3'S,6'S,3''R,6''S)-1'-Benzyl-5'-ethoxy-6'-hydro-6'-isopropyl-3'-methylpyrazin-3'-yl-2'-one]-3-[1''-benzyl-5''-ethoxy-3'',6''-dihydro-6''-isopropylpyrazin-3''-yl-2''-one]propane




$[\alpha]_D -56.7$ (*c* 1.014, H₂O)

Source of chirality: L-valine

Absolute configuration: 2R,6R assigned by ¹H NMR



Tripeptide [(HO)Val-(2R,6R)-DAP-Val(OH)]·2HCl




$C_{20}H_{38}Cl_2N_4O_6$
Tripeptide [(HO)Val-(2R,6R)-2-allyl-2,6-DAP-Val(OH)]·2HCl

$[\alpha]_D -26.1$ (*c* 0.6, 1N HCl)

Source of chirality: L-valine

Absolute configuration: 2*R*,6*R* assigned by 1H NMR




$C_{19}H_{36}Cl_2N_4O_8$
Tripeptide [(HO)Val-(2R,6R)-2-carboxymethylene-2,6-DAP-Val(OH)]·2HCl

$[\alpha]_D -41$ (*c* 1.16, 1N HCl)

Source of chirality: L-valine

Absolute configuration: 2*R*,6*R* assigned by 1H NMR



$C_{18}H_{36}Cl_2N_4O_6$
Tripeptide [(HO)Val-(2R,6R)-2-methyl-2,6-DAP-Val(OH)]·2HCl

$[\alpha]_D -29.5$ (*c* 0.51, 1N HCl)

Source of chirality: L-valine

Absolute configuration: 2*R*,6*R* assigned by 1H NMR